Belimumab in systemic lupus erythematosus

被引：23

作者：

Vilas-Boas, Andreia ^{[1
]}

Morais, Sandra A. ^{[1
]}

Isenberg, David A. ^{[2
]}

机构：

[1] Hosp Pedro Hispano, Internal Med Dept, Matosinhos, Portugal

[2] Univ Coll London Hosp, Ctr Rheumatol, London, England

来源：

RMD OPEN | 2015年 / 1卷 / 01期

关键词：

D O I：

10.1136/rmdopen-2014-000011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.

引用

页数：6

共 49 条

[1] BAFF mediates survival of peripheral immature B lymphocytes [J].

Batten, M ;

Groom, J ;

Cachero, TG ;

Qian, F ;

Schneider, P ;

Tschopp, J ;

Browning, JL ;

Mackay, F .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (10) :1453-1465

[2] Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL [J].

Benson, Micah J. ;

Dillon, Stacey R. ;

Castigli, Emanuela ;

Geha, Raif S. ;

Xu, Shengli ;

Lam, Konk-Peng ;

Noelle, Randolph J. .

JOURNAL OF IMMUNOLOGY, 2008, 180 (06) :3655-3659

[3] EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics [J].

Bertsias, G. ;

Ioannidis, J. P. A. ;

Boletis, J. ;

Bombardieri, S. ;

Cervera, R. ;

Dostal, C. ;

Font, J. ;

Gilboe, I. M. ;

Houssiau, F. ;

Huizinga, T. ;

Isenberg, D. ;

Kallenberg, C. G. M. ;

Khamashta, M. ;

Piette, J. C. ;

Schneider, M. ;

Smolen, J. ;

Sturfelt, G. ;

Tincani, A. ;

van Vollenhoven, R. ;

Gordon, C. ;

Boumpas, D. T. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :195-205

[4] Elevated Serum BAFF Levels Are Associated With Rising Anti-Double-Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus [J].

Carter, Lucy M. ;

Isenberg, David A. ;

Ehrenstein, Michael R. .

ARTHRITIS AND RHEUMATISM, 2013, 65 (10) :2672-2679

[5] The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe [J].

Cervera, R. ;

Khamashta, M. A. ;

Hughes, G. R. V. .

LUPUS, 2009, 18 (10) :869-874

[6]

Chan O, 1998, J IMMUNOL, V160, P51

[7] A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus [J].

Chan, OTM ;

Hannum, LG ;

Haberman, AM ;

Madaio, MP ;

Shlomchik, MJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (10) :1639-1647

[8] Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial [J].

Chatham, W. Winn ;

Wallace, Daniel J. ;

Stohl, William ;

Latinis, Kevin M. ;

Manzi, Susan ;

McCune, W. Joseph ;

Tegzova, Dana ;

McKay, James D. ;

Avila-Armengol, Hilario E. ;

Utset, Tammy O. ;

Zhong, Z. John ;

Hough, Douglas R. ;

Freimuth, William W. ;

Thi-Sau Migone .

JOURNAL OF RHEUMATOLOGY, 2012, 39 (08) :1632-1640

[9] Systemic Activation of the Immune System Induces Aberrant GAFF and APRIL Expression in B Cells in Patients With Systemic Lupus Erythematosus [J].

Chu, Van Trung ;

Enghard, Philipp ;

Schuerer, Stefanie ;

Steinhauser, Gudrun ;

Rudolph, Birgit ;

Riemekasten, Gabriela ;

Berek, Claudia .

ARTHRITIS AND RHEUMATISM, 2009, 60 (07) :2083-2093

[10] Reproductive and menopausal factors and risk of systemic lupus erythematosus in women [J].

Costenbader, Karen H. ;

Feskanich, Diane ;

Stampfer, Meir J. ;

Karlson, Elizabeth W. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (04) :1251-1262

← 1 2 3 4 5 →